Document Detail

Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.
MedLine Citation:
PMID:  20170597     Owner:  NLM     Status:  MEDLINE    
Prostate cancer is a highly prevalent malignancy. Using serum prostatic-specific antigen (PSA) levels to screen for prostate cancer has led to a greater detection of this cancer, at earlier stages. However, screening for prostate cancer by determining PSA levels remains controversial. Concerns include the risk of overdiagnosis and conversely, the failure to detect all prostate cancers. This article, aimed at primary care practitioners, reviews the characteristics of an ideal screening test, in relation to the characteristics of the PSA test. It then discusses the implications of recent findings from two large, randomized, prospective screening trials: the American Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trial and the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial. The latter trial demonstrated a modest survival benefit from PSA screening. Lastly, the article summarizes recommendations from recently updated guidelines about PSA testing from the American Urological Association (AUA), and it discusses when a primary care practitioner might refer a patient to a urologist.
John S Kell
Related Documents :
15540737 - Race is not a predictor of prostate cancer detection on repeat prostate biopsy.
12656897 - Differences in biopsy features between prostate cancers located in the transition and p...
11326167 - Prostate cancer: screening and early detection.
17269617 - Pathological aspects of prostate cancer aggressive behavior. personal experience in dif...
15540737 - Race is not a predictor of prostate cancer detection on repeat prostate biopsy.
22258477 - Surveillance of demographic characteristics and health behaviors among adult cancer sur...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Canadian journal of urology     Volume:  17 Suppl 1     ISSN:  1195-9479     ISO Abbreviation:  Can J Urol     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-22     Completed Date:  2010-05-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9515842     Medline TA:  Can J Urol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  18-25     Citation Subset:  IM    
Division of Urology, Toronto East General Hospital, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Distribution
Attitude of Health Personnel
Early Detection of Cancer / standards,  trends
Mass Screening / methods*
Middle Aged
Physician's Practice Patterns
Physicians, Family / trends
Primary Health Care / methods*,  trends
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / diagnosis*,  epidemiology,  prevention & control
Risk Assessment
Sensitivity and Specificity
Survival Rate
Reg. No./Substance:
EC Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Overactive bladder symptoms in women: current concepts in patient management.
Next Document:  Management of benign prostatic hyperplasia by family physicians.